Key Points
- On May 1, Ultragenyx CFO Howard Horn sold 4,683 shares at an average price of $24.90 for about $116,607, reducing his stake by 4.07% to 110,342 shares (≈$2.75M), according to an SEC filing.
- The sale is one of several Horn disposals in March–April and comes as Ultragenyx reports negative EPS despite 25.5% year‑over‑year revenue growth; the company has a $2.44B market cap and mixed analyst views (consensus "Moderate Buy" with a $60.76 target, while Goldman Sachs recently cut to neutral with a $25 target).
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Get Free Report) CFO Howard Horn sold 4,683 shares of the firm's stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $24.90, for a total value of $116,606.70. Following the transaction, the chief financial officer owned 110,342 shares of the company's stock, valued at approximately $2,747,515.80. The trade was a 4.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Howard Horn also recently made the following trade(s):
- On Wednesday, April 1st, Howard Horn sold 4,683 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $20.97, for a total value of $98,202.51.
- On Tuesday, March 3rd, Howard Horn sold 1,635 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $22.40, for a total value of $36,624.00.
- On Monday, March 2nd, Howard Horn sold 8,409 shares of Ultragenyx Pharmaceutical stock. The shares were sold at an average price of $22.70, for a total value of $190,884.30.
Ultragenyx Pharmaceutical Stock Up 0.2%
Shares of Ultragenyx Pharmaceutical stock opened at $24.81 on Tuesday. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -4.25 and a beta of 0.39. The business has a 50-day moving average price of $22.50 and a 200-day moving average price of $26.96. Ultragenyx Pharmaceutical Inc. has a twelve month low of $18.29 and a twelve month high of $42.37.
Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last issued its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.09). The firm had revenue of $207.28 million for the quarter, compared to analysts' expectations of $199.60 million. Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The company's revenue for the quarter was up 25.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.39) EPS. On average, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post -4.49 EPS for the current fiscal year.
Institutional Trading of Ultragenyx Pharmaceutical
Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 10,263,815 shares of the biopharmaceutical company's stock valued at $236,068,000 after acquiring an additional 131,087 shares in the last quarter. State Street Corp raised its stake in shares of Ultragenyx Pharmaceutical by 16.5% during the fourth quarter. State Street Corp now owns 4,303,046 shares of the biopharmaceutical company's stock valued at $98,970,000 after acquiring an additional 610,559 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of Ultragenyx Pharmaceutical by 26.6% during the fourth quarter. Wellington Management Group LLP now owns 2,461,910 shares of the biopharmaceutical company's stock valued at $56,624,000 after acquiring an additional 516,781 shares in the last quarter. Assenagon Asset Management S.A. raised its stake in shares of Ultragenyx Pharmaceutical by 1,030.4% during the first quarter. Assenagon Asset Management S.A. now owns 2,257,671 shares of the biopharmaceutical company's stock valued at $47,298,000 after acquiring an additional 2,057,951 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. raised its stake in shares of Ultragenyx Pharmaceutical by 614.1% during the third quarter. Jacobs Levy Equity Management Inc. now owns 2,167,729 shares of the biopharmaceutical company's stock valued at $65,205,000 after acquiring an additional 1,864,164 shares in the last quarter. Institutional investors own 97.67% of the company's stock.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the company. The Goldman Sachs Group lowered Ultragenyx Pharmaceutical from a "buy" rating to a "neutral" rating and cut their price objective for the company from $61.00 to $25.00 in a research report on Tuesday, March 24th. Barclays dropped their price target on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an "overweight" rating for the company in a research report on Wednesday, April 29th. Weiss Ratings lowered Ultragenyx Pharmaceutical from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Friday, April 24th. Morgan Stanley lifted their price target on Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the stock an "overweight" rating in a research report on Thursday, April 16th. Finally, Truist Financial upgraded Ultragenyx Pharmaceutical to a "strong-buy" rating in a research report on Wednesday, March 25th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $60.76.
Read Our Latest Report on RARE
About Ultragenyx Pharmaceutical
(
Get Free Report)
Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.
The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
